Blastic phase of chronic myelogenous leukemia

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 7, 2005, Pages 547-552

  Morris, Evelyn L ^c   Dutcher, Janice P ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Our Lady of Mercy Cancer Center   (United States)

^c NONE

Author keywords

Blast crisis; Chronic myeloid leukemia; Philadelphia chromosome; Therapy

Indexed keywords

AZACITIDINE; BCR ABL PROTEIN; CARBOPLATIN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; METHYLPREDNISOLONE; MITHRAMYCIN; MITOXANTRONE; PROTEIN P53; RETINOIC ACID;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER THERAPY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; ONCOGENE C MYC; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT OUTCOME;

BLAST CRISIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; REMISSION INDUCTION;

EID: 27644500425     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Anastasi J, Feng J, Le Beau MM, et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995;9:628-33.
2. Arlin ZA, Silver RT, Bennett JM. Elastic phase of chronic myeloid leukemia (blCML): a proposal for standardization of diagnostic and response criteria. Leukemia. 1990;4:755-757.
3. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
4. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
5. Giles FJ, Cortes JE, Kantarjian HM, et al. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753-774.
6. Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukemia (CML) in accelerated or blastic phase-a report from the Swedish CML group. Br J Haematol 2002;118:1048-54.
7. Bolaman Z, Koseoglu M, Ayyildiz O, et al. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methyl-prednisolone. Hematologica. 2002;32:49-57.
8. Dutcher JP, Eudey L, Wiernik PH, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia. 1992;6:770-775.
9. Kantarjian HM, Walters RS, Keating MJ, et al. Treatment of blastic p hase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988;62:672-676.
10. Druker BJ, Sawyers CL, Kantarjian HM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
11. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
12. Kamada N, Takechi M, Kudo S. [Review: progress of cytogenetics in hematopoietic malignancies] Nippon Rinsho. 1992;50:1267-1273.
13. Kurzrock R, Talpaz M. The molecular pathology of chronic myelogenous leukaemia. Br J Haematol. 1991;79:34-37.
14. Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138:819-830.
15. Anger B, Carbonell F, Braunger I. Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML): treatment results of 69 patients. Blut. 1988;7:131-137.
16. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18:545-568.
17. Kantarjian HM, Talpaz M, Gutterman J, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high does cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992;10:398-405.
18. Greisshamer M, Heinze B, Hellmann A, et al. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol. 1996;73:225-230.
19. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med. 1987;83:445-454.
20. Rosenthal S, Canellos GP, Whang-Peng J, et al. Blast crisis of chronic granulocytic leukemia: morphologic variants and therapeutic implications. Am J Med. 1977;63:542-547.
21. Randhawa GS, Cui H, Barletta JA, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998;91:3l44-l47.
22. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.
23. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-667.
24. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
25. Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 2000;95:738-743.
26. Karanas A, Silver RT. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968;32:445-59.
27. Dutcher JP, Wiernik PH. Accelerated and blastic phase of chronic myeloid leukemia. Curr Treat Options Oncol. 2000;1:51-62.
28. Dutcher JP, Wiernik PH, Strauman JJ, et al. Mitoxantrone and cytosine arabinoside in acute non-lymphocytic leukemia and blast crisis of chronic myelogenous leukemia. Proc Am Soc Clin Oncol. 1985;4:170.
29. Morris EL, Dutcher JP, Paietta E, et al. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. 2005. [In preparation]
30. Robak T, Gora-Tybor J. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia. Neoplasma. 2001;48:203-207.
31. Goldberg J, Gryn J, Raza A, et al. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL/CML in blast crisis: a leukemia intergroup study. Am J Hematol 1993;43:286-290.
32. Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep. 1982;66:267-271.
33. Dutcher JP, Lee S, Paietta E, et al. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group study (E 1992). Leukemia. 1998;12:1037-1040.
34. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med. 1986;315:1433-1438.
35. Dutcher JP, Lee S, Wiernik PH, et al. Phase II study of All-Trans retinoic acid (ATRA) in accelerated phase or early blastic phase of chronic myeloid leukemia. A study of the Eastern cooperative Oncology group (E1993). Leuk Lymphoma. 2005;46:377-85.
36. Fefer A, Clift RA, Thomas ED. Allogeneic marrow transplantation for chronic granulocytic leukemia. J Natl Cancer Inst. 1986;76:1295-1299.
37. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202-207.
38. Kantarjian HM, Cortes JE, O'Brien S, et al. Long- term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979-1988.
39. Marin D, Marktel S, Bua M, et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologlca. 2002;87:979-988.
40. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica. 2003;88:1213-1220.
41. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
42. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
43. Zhang GC, Zheng D, Li QH, et al. Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase [in Chinese]. Ai Zheng. 2004;23:1696-1699.
44. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Update. 2003;6:231-238.
45. Breccia M, Nanni M, Mancini F, et al. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica. 2004;89:ECR11.
46. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma. 2004;45:401-403.
47. Bornhauser M, Jenke A, Freiberg-Richter J, et al. CNS blast crisis of chr onic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol. 2004;83:401-402.
48. Avery S, Nadal E, Marin D, et al. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. Leuk Res. 2004;1:S75-S77.
49. Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45:695-698.
50. Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003;9:4674-4681.
51. Yoshida C, Melo JV. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol. 2004;79:420-433.
52. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003;10:3765-3774.
53. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 2004;104:509-518.